65,437 trials
Urinary Bladder Neoplasms
Primary: Cohort 1: Recurrence-Free Survival (RFS) — NA; 11.60 Months — p==0.0007
Acute Pain
Primary: Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to Placebo — 70.6…
Lymphoma, Large B-Cell, Diffuse · Lymphoma, Follicular · Lymphoma, Mantle-Cell
Primary: Number of Patients With a Clinically Meaningful Reduction in Lung Toxicity, Defined as a Reduction of the Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) by at…
Barrett's Esophagus · Esophageal Squamous Dysplasia · Esophageal Cancer
Primary: Number of Participants With Complete Eradication of Esophageal Dysplasia — 51 Participants
Alzheimer Disease · Cognitive Impairment
Primary: Change in Neuro-QoL Positive Affect and Well-Being Score — 55.41; 56.22; 55.51; 56.83 T-Score — p=.7695
Alzheimer Disease
Primary: Regional SUVR Value for 18F-MK-6240 — 1.27 SUVR
Vaping
Primary: Visual Attention — 6217.016667; 6333.70375; 6567.725714; 6667.185625 milliseconds
IPV · Perinatal · Mental Health
Primary: Composite Abuse Scale (CAS) — 29.13; 27.01; 10.54; 10.02 units on a scale — p=>0.05
Opioid-use Disorder
Primary: The Primary Endpoint Will be Safety and Tolerability of CBD. — 13; 4 participants
Pulmonary Hypertension
Primary: Identify Equivalent Dose of VentaProst Necessary to Achieve a PD Response Comparable to Standard of Care Treatment (Part I) — 17 ng/kg/min
Coronary Artery Disease
Primary: Platelet Reactivity Measured as PRU — 154.5; 23; 104 PRU
Hearing Impairment
Primary: Paired Difference in dB SRT Between the CP1170 SCAN 2 FF (Automated ForwardFocus ON) and CP1170 SCAN 2 (ForwardFocus OFF) in 65 dB SPL (Sound Pressure Level) S0Nrearhalf…
Smoking Cessation
Primary: Biochemically-Verified Smoking Cessation — 37; 23 Participants
Hearing Loss, Conductive · Hearing Loss, Mixed
Primary: To Investigate the Improvement in Hearing With the Ponto 4 (s) on the Implanted Ear for Patients Within Intended Use. — 31.5 [dB]
Rheumatoid Arthritis
Primary: Incidence Rate of Low Disease Activity (LDA) or Remission Based on Clinical Disease Activity Index (CDAI) at 6-Months Follow-up: Tofacitinib vs. TNFi — 426.8; 471.9…